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A large number of chemicals induce or exacerbate autoimmune-like diseases in man. Because of
the complexity of processes involved, these adverse effects are often if not always missed in
standard toxicity testing. To date no validated and generally applicable predictive animal model
exists and only a few chemicals have actually been shown to induce adverse autoimmune effects in
certain animals. The popliteal lymph node assay (PLNA) is a very promising animal test to
(pre)screen for systemic immunosensitizing, including autoimmunogenic potential. This review
describes the essentials of the various PLNAs against the background of current understanding of
chemically induced systemic immunostimulation. The most simple primary PLNA measures
enlargement of the popliteal lymph node 6-8 days after subcutaneous injection of a chemical into
the footpad. The primary PLNA can distinguish between immunostimulating (both sensitizers and
irritants) and innocent chemicals but does not assess the involvement of T cells or
immunosensitization. For this, but also for elucidation of relevant mechanisms, detection of
anamnestic responses in secondary PLNAs or responses to reporter antigens in the modified PLNA
are suitable. To date over 100 compounds (drugs and environmental pollutants) have been tested,
and results show a good correlation with reported immunostimulating (both autoimmunogenic and
allergic) potential. Importantly, no false-negative chemicals were detected if metabolism was
considered. The various types of the PLNA, but in particular the secondary and modified PLNAs,
await extensive validation before they can be recommended as a standard test for
autoimmunogenic potential. Key words: autoimmunity, chemicals, popliteal lymph node assay,
reporter antigens. - Environ Health Perspect 107(suppl 5):673-677 (1999).
http.//ehpnet1.niehs.nih.gov/docs/1999/suppl-5/673-677pieters/abstract html
Various drugs and environmental chemicals or
metabolites thereofcollectively referred to as
low molecular weight compounds [LMWCs]
generally less then 1,000 Da can provoke the
onset ofautoimmune diseases (AID) (1-4).
The pathogenesis ofAID is a multifactorial
and complex process, involving a large num-
ber ofpredisposing factors (major histocom-
patabiitycomplex [MHC] haplotype, gender,
metabolism, concurrent infections). Not sur-
prisingly, it has proven very difficult to
develop animal models that mimic certain
AID, let alone LMWC-induced AID.
Consequently, no generally applicable predic-
tive animal models exist using symptomatic
AID as an end point and achemical's capacity
to induce or exacerbate AID in man is hardly
ifever recognized in standard toxicity testing
(1). Reasonably, predictive test models for
autoimmunogenic potential ofxenobiotics
should rely on detection ofinitiating immune
responses rather than on symptomatic AID.
The presently available popliteal lymph node
assays (PLNAs) are very promising test sys-
tems that focus largelyon initiating immunos-
timulatoryeffects ofchemicals.
Autoimmune diseases are the ultimate
clinical consequence ofdestructive immune
responses triggered by unregulated adaptive
responses to autoantigens (1,2,5). These unreg-
ulated adaptive immune responses are the con-
sequence ofbreakthrough ofimmunologic
tolerance and subsequent activation ofautore-
active lymphocytes. According to current
understanding in immunology, lymphocytes
require two signals to become activated. Signal
1 is provided by receptors upon recognition of
a specific antigen and signal 2 is antigen-non-
specific and provided by costimulatory mole-
cules and cytokines. Peripheral and probably
also central tolerance is accomplished by
recognition ofan adequate antigen or recep-
tion ofsignal 1 in the absence ofa nonspecific
costimulatory or "helping" signal 2 (5,6).
Consistently, induction of self-tolerance
involves specific recognition of autoantigen
leading to selective inactivation or destruction
ofautoreactive lymphocytes, and tolerance
only exists for dominant autoantigens/epi-
topes. Signal 2 alone does not elicit an
immune reaction (7).
To fully understand the strengths but also
the limitations ofthe PLNA, we need to con-
sider how the generation ofsignal 1 and/or 2
is incorporated into our present understand-
ingofchemical-induced immunostimulation.
Generaflion ofNeoepitopes orSignal 1
Generally, LMWCs are too small to function
as antigen by themselves, but provided that
they are chemically reactive, they may bind to
(self-)proteins, thus forming a hapten-carrier
complex or chemically alter a (self-)protein
otherwise. The self-protein can, for example,
be a peptide-presenting MHC molecule to
which the reactive chemicals can bind directly.
Alternatively, LMWCs can influence antigen
presentation so that previously cryptic epitopes
are presented by the MHC molecules on
antigen-presenting cells (APCs). These hap-
ten-carrier complexes and cryptic epitopes are
recognized as new, therefore collectively desig-
nated as neoantigens or neoepitopes, and they
can elicit signal 1 in neospecific T and B cells
(7). Provided a costimulatory or second signal
is induced by the chemical, immunostimula-
tion and immunosensitization mayfollow.
GenerationofCostimulation
orSignal 2
Many if not all autoimmunogenic LMWCs
can directly elicit immune responses without
requiring additional stimulators (see "Popliteal
Lymph Node Assays"). This indicates that
these LMWCs have intrinsicadjuvant activity,
which is also obvious because they induce an
inflammation upon subcutaneous injection in
the paw. This proinflammatory property of
chemicals may in certain cases suffice to acti-
vate antigen-presenting dendritic cells and
neoantigen-specific and autoreactive lympho-
cytes. In the underlying processes, costimula-
tory molecules on the surface ofdendritic cells
as well as immunomodulating cytokines also
designated as second signals, are thought to be
ofpivotal importance.
The B cell as a costimulatory APC is
considered to play a crucial role in eliciting
autoantigen-specific immune reactions upon
initial neoantigen-specific immunostimulation.
A B-cell that presents an altered MHC mole-
cule (a neoantigen) may receive ahelpingsignal
2 from the respective neoantigen-specific Tcell.
In case the B cell recognizes an unaltered
autoantigen with repetitive epitopes that cross-
links B-cell receptors (a so-called T-cell-
independent type 2 antigen), the B cell will
start to produce antigen-specific antibodies
with a switched isotype. Among these T-
cell-independent type 2 antigens are autoanti-
gens such as DNA molecules or collagen.
Notably, this type ofimmune response resem-
bles noncognate stimulation provided by graft
T-helper (Th) cells activated by allogeneic
MHC molecules on host B cells during graft
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versus host reactions. Clinical symptoms
observed in chemical-induced systemic
autoimmune derangements often resemble
those seen in graftversus host disease (8).
The B cell may also directly recognize a
neoepitope or aself-epitope ofthe neoantigen
with its antigen-specific receptor. This B cell
will then present a mixture ofaltered and
unmodified autoantigens complexed to dis-
tinct MHC-II molecules on its surface.
Initially, only neoantigen-specific Th cells
will provide a helping signal 2 to the B cell.
As a result, the B cell will start producing
either neoantigen- or autoantigen-specific
antibodies. More relevant in this case, the B
cell also becomes an efficient APC expressing
an effective level ofcostimulatory molecules.
As a result ofthe latter, the B cell can provide
a signal 2 that activates previously silent
autoreactive Th cells. This process ofchang-
ing specificity of a neoantigen-specific
immune response to include autoantigens is
an example ofepitope or determinant spread-
ing (9). As a result ofthis process, neoanti-
gen- and autoantigen-specific T cells are
concurrently present in immunosensitized
animals. This would imply that the distinc-
tion between allergic and autoimmune
responses induced by LMWCs can only be
gradual, reflecting the relative antigenicity of
the neoantigens and autoantigens involved.
In conclusion, reactive LMWCs are able
to give rise to either signal 1 or 2 or both, but
as signal 1 by itselfleads to inactivation of
specific lymphocytes, induction ofcostimula-
tion (i.e., signal 2) may be regarded as more
decisive in the initiation of (auto)immune
responses than the nature ofthe neoantigens
involved (5).
It is important to realize is that induction
ofan autoimmune response alone is not suffi-
cient to get an AID and usually autoimmune
responses are downregulated to fade away.
Obviously, other factors are involved as well.
For examplea number ofLMWCs modulate
not only initiating events but also the produc-
tion ofregulatory cytokines [for example,
HgCl2 stimulates interleukin-4 production by
mast cells (10)] or effector mechanisms [for
example, procainamide and D-penicillamine
inhibit complement factor C4 (11)].
Popliteal Lymph NodeAssays
At present, basically three variations ofthe
PLNA can be recognized (Figure 1): the pri-
mary or simple PLNA, the secondary PLNA,
and the modified PLNA.
ThePrimaryPLNA
The primary PLNA is the most simple varia-
tion and is recommended in the screening of
immunostimulating potential of, for instance,
newlysynthesized drugs. In theprimaryPLNA,
the cell number in the popliteal lymph node
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Figure 1. Simplified representation of various popliteal lymph node assays. Of the secondary PLNAs, only the adop-
tive transfer PLNA is depicted. ELISPOT assay, enzyme-linked spot assay; PLNA, popliteal lymph node assay. See text
forfurther details.
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Figure 2. In the modified PLNA, eitherTNP-Ficoll orTNP-OVA is injected togetherwith the chemical. Abbreviations:
OVA, ovalbumin; PLNA, popliteal lymph node assay; TNP, 2,4,6-trinitrophenyl, As aT-cell-independenttype 2 antigen
that cannot be recognized by T cells, TNP-Ficoll delivers a strong signal 1 to the B cell so thatthis cell will produce
TNP-specific IgM antibodies. However, to form switched isotypes (IgGl, IgG2a, or IgE), the TNP-specific B cell
requires helpfrom Tcells, which in the case of injection of low molecularweightcompounds are neoantigen specific.
TheT-cell-dependent antigen TNP-OVA can be recognized by B cells aswell as byTcells, butthe dose ofTNP-OVA
is too low to elicit a measurable immune response. To get an optimal antibody production toward TNP-OVA, adju-
vant signals such as inflammatorycytokines are needed.
(PLN) or the weight ofthe PLN is measured
usually 1 week (6-8 days) after the test chemi-
cal (without additional adjuvant) is subcuta-
neously injected into one hind footpad ofthe
test animal, either a mouse or a rat. Control
animals are treated similarlywith the respective
vehide only and the ratio (PLN index) ofthe
response in treated versus control animals is a
measureforimmunostimulation.
Although the primary PLNA is capable of
distinguishing immunostimulating from
innocent chemicals, this assayin its mostsim-
ple form fails to distinguish haptens or
neoantigen-forming chemicals from mere
inflammatory irritants. This deficit in dis-
criminating these various types ofchemicals
may hamper proper hazard assessment and
mechanism-based risk assessment and can be
circumvented by direct measurement of
T-cell-dependent immune reactions in the
primary PLNA or the involvement ofT cells
in either thesecondaryormodified PLNA.
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TheSecondaryPLNA
Secondary responses inpreviously sensitized
animals. In the secondary PLNA, a previ-
ously sensitized animal is challenged with a
suboptimal dose of the same chemical.
Sensitization can be done by subcutaneous
injection into the footpad as in the primary
PLNA. Assessment ofthe specific anamnestic
immune response, being faster in kinetics
than a primary immune response, is deter-
mined as a PLN index within 4-6 days.
Theadoptive transferPLNA. The adoptive
transfer PLNA demonstrates the involvement
of T cells in a straightforward manner.
Briefly, splenic T cells from previously sensi-
tized animals are injected into the footpad of
naive syngeneic recipient mice 1 day before a
nonsensitizing dose ofthe same LMWC or a
reactive metabolite is injected into the same
footpad. The PLN index is again measured
4-6 days later. This PLNA appears suitable to
combine with sensitization via a relevant
route of exposure, which has been done for
example, intramuscularly with Au(I) salts
[reviewed in Bloksma et al. (12)].
The adoptive transfer PLNA has been
used extensively by Gleichmann and col-
leagues, and in addition to proving the
involvement ofT cells for some chemicals
they were also able to eliminate a number of
false-negative autoimmunogenic chemicals
(procainamide, propylthiouracil [PTU], and
Au+) bydetecting memory T-cell responses to
their metabolites (n-hydroxyl-amino-pro-
cainamide), PTU-SO3-, Au3+) (13-15).
These false-negative LMWC appeared to
require bioactivation, which apparently is not
sufficiently available in the uninflamed paw.
Bioactivation, however, can be easily intro-
duced into the PLNA by coinjection ofan S9
mix oractivated phagocytes.
Results obtained with the adoptive PLNA
have also shown that mice immunized with
the untreated non-self-model antigen bovine
RNase in adjuvant respond exclusively to
dominant epitopes, whereas injection of
RNase preincubated withAu(III) elicits addi-
tional T-cell responses to cryptic epitopes
(16). Using the adoptive transfer PLNA, it
was also demonstrated that T cells, isolated
shortly after initiating an autoimmune
response with HgC12, responded exclusively
to unidentified mercury-modified self-
proteins; later in the response, T cells
responding to unmodified self-proteins were
detectable as well (17). The first study shows
that autoimmunogenic chemicals can provide
signal 1 by releasing cryptic epitopes. The
second study demonstrates that the immune
response can spread from a hapten- or
neoantigen-specific to a autoantigen-specific
immune response. Together, they illustrate
the usefulness of the adoptive transfer PLNA
in increasing the fundamental knowledge of
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Figure 3. Comparison of the immune response to reporter antigens TNP-Ficoll and TNP-OVA induced by a number of
nonsensitizing irritants, allergenic, and autoimmunogenic chemicals. Abbreviations: AFC, antibody-forming cells; IFA,
incomplete Freund's adjuvant; OVA, ovalbumin; TNP, 2,4,6-trinitrophenyl. Results are expressed as the number of
antibody-forming cells per 106 popliteal lymph node cells, measured by enzyme-linked SPOT assay. Of note, strepto-
zotocin stimulates a Thl-driven immune response, hence the occurrence of IgG2a instead of IgGl isotype.
Table 1. List of chemicals tested in the popliteal lymph node assay.
Category Chemicalsa No.b Literature
Vehicles Dimethylsulfoxide, ethanol, acetone,c saline 4 (18,22,23);
Figure 3
Antiarrhythmic PAand metabolites n-acetyl-PA and n-hydroxylamino-PA 3 (14,18,23)
Antihypertensive Hydralazine 1 (23,35)
Antituberculous Isoniazid, p-aminosalicylic acid 2 (23)
Antipsychotic Chlorpromazine 1 (23)
Anticonvulsant Diphenylhydantoin+ 43 structural derivatives 50 (22,23)
methsuximide, ethosuximide, phensuximide
carbamazepine, phenobarbital, denzimol
Antirheumatic D-Penicillamine 1 (18,34)
Antithyroid Propyithiouracil and its metabolite propylthiouracil- 2 (15)
sulfonate
Anti-inflammatory Phenylbutazone, monophenylbutazone, 1-phenyl-3-pyrazolidone, 5 (23,35)
ibuprofen, diclofenac
Antibacterial Nitrofurantoin 1 (18)
Analgesic Glafenine 1 (35)
Antihelminthic Quinacrine, levamisole 2 (23)
Antischistosomal Niridazole 1 (23)
Alcohol deterrent Disulfiram 1 (23)
Allergic, Dinitrochlorobenzene; oxazolone; trimelliticanhydride; 15 (23,36); Figure 3
contactsensitizers a-methylene-y-butyrolactone (tulipalineJ, p-phenylenediamine;
5-nitro-2-furaldehyde semicarbazone; mercaptobenzothiazol;
carbanilide; diethyidithiocarbamate sodium; 1,3-dimethyl-2-
thiourea; 1,3-diethyl-2-thiourea; 1,3-dibutyl-2-thiourea;
1-phenyl-3-[2-thiazolyl]-2-thiourea; hexachloroplatinate
Antidepressants Zimeldine+ 18 structural homologs, paroxetine, fluvoxamine, 30 (24-27)
imipramine, maprotiline, nortriptyline, clomipramine, LiCI,
amitriptyline, nomifensine, ritanserin, serotonin
Metals HgCI2,Au+, Au+(metabolite ofAu+), NiCI2, CuCI2 5 (13,16,18,
19,32,33)
Antineoplastic Streptozotozin 1 (18); Figure 3
Environmental 2,3,7,8-TCDD, HCB, silica, dieselexhaustparticles 5 (28-31)
pollutants
Miscellaneous LPS, IFA, CFA, glutaricanhydride, SDS, 4 (28-31)
dichloronitrobenzene (innocent homolog of DNCB)
Total 131
Abbreviations: CFA, complete Freund's adjuvant; DNCB, dinitrochlorobenzene; HCB, hexachlorobenzene; IFA, incomplete Freund's
adjuvant; LPS, lipopolysaccharide; PA, procainamide; SDS, sodium dodecyl sulfate; 2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
*False-positive (unbroken) and false-negative (dotted) chemicals are underlined. Compounds tested in the modified PLNA are shown in
italics, and chemicals tested in one of the secondary PLNAs are in bold. bNumber of tested chemicals without vehicles. CPositive in
pure concentrations, butwhen used in concentrations lowerthan 20% (v/v)diluted in saline, they are negative.
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processes ofchemical-induced autoimmune
responses.
However, although the adoptive transfer
PLNA is a very useful test, it is not suitable in
the screening phaseofchemical testing because
it requires large numbers ofdonor animals and
aconsiderable amount oftechnical skill.
TheModifiedPLNA
In the recently introduced modified
PLNA, the local 2,4,6-trinitrophenyl (TNP)-
specific antibody response to well-defined anti-
gens TNP-ovalbumin (TNP-OVA) or
TNP-Ficoll isanalyzedafter coinjectionwith a
given LMWC (18). These antigens are chosen
because they need different and (in relation to
LMWC-induced autoimmune responses) rele-
vant conditions to elicit a TNP-specific anti-
body response. A TNP-specific IgG response
to theT-cell-independent antigenTNP-Ficoll
can only occur in the presence ofT-cell help,
which is noncognate. Hence, in case of
co-injection with an LMWC, a TNP-specific
IgG reponse to TNP-Ficoll indicates soluble
help fromhapten ofneoantigen-specific Tcells
(Figure2) (26).
The T-cell-dependent antigen TNP-
OVA, which requires cognate T-B cell inter-
action, is used in such a low dose (10
pg/mouse) that itdoes not cause a measurable
immune response by itself. To get a TNP-
specific antibody response to this low concen-
tration of TNP-OVA, costimulatory
adjuvant signals are needed, which may arise
from inflammatory responses induced by a
reactive chemical. So any reactive LMWC
that induces an inflammation, including non-
sensitizing irritant chemicals or adjuvants,
will induce an IgG response to TNP-OVA.
The IgG response to these two reporter
antigens may be used to discriminate between
compounds that create neoantigens and
thereby activate T cells (positive IgG response
to both TNP-Ficoll and TNP-OVA, e.g.,
HgC12 [Figure 3]) and compounds that only
cause an inflammatory response and do not
sensitize neoantigen-specific T cells [positive
response to TNP-OVA but not to TNP-
Ficoll, e.g., the irritant glutaric anhydride or
the macrophage stimulator silica (Figure 3)]
(18). Surprisingly, the classic irritant sodium
dodecyl sulfate induced a IgG1 response to
TNP-Ficoll, suggesting that this compound
induces formation of neoantigens upon
subcutaneous exposure (Figure 3).
The modified PLNA with TNP-OVA
has anumber ofadditional advantages:
In comparison to the number oflymph
node cells, which ranges from 1 x 106
cells/node in controls to 20 x 106
cells/node in treated mice, the increase of
the IgG response to this reporter antigen,
which is measured as the numberofTNP-
specific antibody-forming cells (AFC), is
Objective
Screen an arrayof
(homologous) chemicals
for immunostimulatory
potential
Tool
Primary PLNA
Discriminates between
immunostimulatory and
innocent chemicals
Interpretation
Ifnegativeconsidermetabolism,
route andtime period of exposure.
If positive, thechemical is
immunostimulatory. No prooffor
immunosensitizing capacity.
|Ifprimary PLNA ispositive and information on T-cell sensitization required:
AssessT-cell involvement
and immunosensitization
Secondary PLNA
in same animal
Modified PLNA
with TNP-Ficoll and
TNP-OVA
Both secondary and
modified PLNA can
discriminate between
immunosensitizing
chemicals and mere
irritant chemicals
Both secondary and modified PLNA
Ifnegative, see comments on
primary PLNA.
Secondary PLNA
If positive, chemical induces an
immunologic memory response.
Modified PLNA
If positiveforTNP-Ficoll, chemical
creates neoantigens and stimulates
T cells.
If only positive forTNP-OVA,
neospecific Tcells are not
involved and the chemical is
likely a mere adjuvating irritant.
Ifsecondary PLNA or response toTNP-Ficoll is positive and proofforrole
ofTcells is required:
AssessT-cell sensitization Adoptive transfer
PLNA
Proves the
involvement of
T-cells in straight
forward manner
If negative, see comments on
primary PLNA.
If positive, crucial role forTcells
proven and the chemical is capable
of immunosensitization.
Figure 4. Flow scheme illustrating the strategy for using the various PLNAs. Abbreviations: OVA, ovalbumin; PLNA,
popliteal lymph node assay; TNP, 2,4,6-trinitrophenyl.
considerably higher and ranges from 10 to
1,000 AFC/10 PLN cells. This improves
discrimination and ranking ofa chemical's
immunostimulatingcapacity.
The type ofimmune response (cellular or
Thl-dependent vs Th2-dependent) stimu-
latedbyachemical can beanalyzedeasilyby
measuringthe isotype specificity ofthe anti-
body response to TNP-OVA (IgG2a for
Thl and IgGI and IgE for Th2). By doing
so, the diabetogen streptozotocin stimulates
an IgG2a response to TNP-OVA in
BALB/c mice, whereas HgCl2 induced
IgGI and also IgE-AFCs to the same anti-
gen inthesamemousestrain (19).
* Byusingcongeneicstrains ofmice, the type
ofthe immune response to TNP-OVAcan
be linked to strain-specific susceptibility to
adverse immune effects induced by a
given LMWC. For example, HgCl2 stim-
ulates a higher IgG1 response to
TNP-OVA in glomerulonephritis-sensi-
tive B1Os (H2s) mice than in resistant
BlOd2 (H2d) mice (20).
* The modified PLNA with TNP-OVA
also allows measuring ofchemical-induced
secondary responses (delayed-type hyper-
sensitivity reactions; antibody-forming
cells in bone marrow, spleen, and lymph
nodes; and serum titers ofTNP-specific
isotypes) (19,20).
Thus, the use ofwell-defined antigens in
the PLNAallows betterhazardidentification of
a chemical's immunostimulating potential and
in addition offers a relatively easy opportunity
to perform mechanistic studies related to
chemical-inducedautoimmunity.
Overall Results Obtained with
the PLNA
Presently, over 100 compounds have been
tested, predominantly in the primary PLNA
and mosdy in the mouse but some also in the
rat (21). The list of compounds (Table 1)
includes many drugs ofvarious categories
[e.g., antiarrhythmics, anticonvulsants
(22,23), antidepressants (24-27)], and struc-
tural homologs of some drugs, but also a
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number ofenvironmental pollutants, i.e.,
hexachlorobenzene (28), 2,3,7,8-tetra-
chlorodibenzo-p-dioxin(29), diesel exhaust
particles (30), and silica (31). Allergenic
compounds (e.g., dinitrochlorobenzene) (23)
also induce a positive PLN index; the
response in the PLNA appears to be dose
dependent (23) and to vary with genetic
background (both MHC and non-MHC
genes) ofthe animals (31-34).
PLN responses show a good correlation
with the reported ability ofa compound to
induce AID or contact dermatitis in man. If
metabolism is considered, no false-negative
LMWC are found. Among the false positives
are strong irritants like ethanol, acetone,
dimethyl sulfoxide (23), and sodium dodecyl
sulfate [(Table 1, Figure 3) unpublished
observations] as well as a few drugs such as
quinacrine and niridazol (23).
Concluding Remarks
To date, no generally applicable predictive
animal models for autoimmunogenic poten-
tial of LMWC exist or are expected in the
near future. However, the immunostimulat-
ing potential ofLMWC can be screened in
the primary PLNA, a simple, rapid, and
objective assay to test an array ofxenobiotics
such as newly synthesized and structurally
homologous drugs. Distinction of the
involvement ofT cells and discrimination
between sensitizing and irritant LMWC can
be accomplished in one ofthe two secondary
PLNAs; however, the adoptive transfer PLNA
cannot be regarded as an early screening
assay. The modified PLNA appears to be a
very promising extension of the primary
PLNA and a simple and fast assay to indicate
the involvement ofT cells. A possible strate-
gic flow scheme that may help to decide
which PLNA is most useful in a certain occa-
sion is depicted in Figure 4.
Positive responses in any of the PLNAs
indicate the potential ofa chemical to stimu-
late the immune system, suggesting that the
chemical may induce AID in genetically pre-
disposed individuals. However, the PLNAs
and in particular the secondary and modified
PLNAs await extensive further validation
before they can be recommended as standard
tests to identify immunostimulatory agents,
including autoimmunogenic chemicals.
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